Royalty Pharma plc Financing Receivable, Allowance for Credit Loss, Recovery
Royalty Pharma plc (RPRX) reported Financing Receivable, Allowance for Credit Loss, Recovery of $457.01 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Notes
us-gaap:FinancingReceivableAllowanceForCreditLossesRecovery · last filed 2020-11-12
- Royalty Pharma plc financing receivable, allowance for credit loss, recovery for the quarter ending 2020-09-30 was $167.42M.
| Period end | Financing Receivable, Allowance for Credit Loss, Recovery 3 month | Financing Receivable, Allowance for Credit Loss, Recovery 6 month | Financing Receivable, Allowance for Credit Loss, Recovery 9 month |
|---|---|---|---|
| 2020-09-30 | $167.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $457.01M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $289.59M 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |